T-DXd for breast cancer that has spread to the brain
Part of Cancer, Skin clinical trials.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have HER2-positive breast cancer that has spread to the brain or other organs.
- Your doctor plans to start you on the drug trastuzumab deruxtecan (Enhertu).
- You must have at least one brain tumor that has not been treated with radiation and can be seen on an MRI.
- Your neurological symptoms (like headaches, weakness, or seizures) must be stable for at least one week, and any medicines for these symptoms (steroids, seizure drugs) must be at a stable dose.
- You must be willing to have a lumbar puncture (spinal tap) and provide a tumor sample (from a biopsy or surgery).
- You cannot have serious lung disease, uncontrolled heart problems, or active hepatitis B or C infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study tests a combination of two targeted therapies—trastuzumab deruxtecan and pyrotinib—as a first treatment for HER2-positive breast cancer that has spread. The goal is to see if this combination helps shrink tumors or delay progression better than current options.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
Hear when a new Central Nervous System (CNS) Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.